Navidea Biopharmaceuticals
our diagnostics and therapeutics pipeline | Navidea Biopharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
May 2022
Slide
5 of 18
Related slides by other companies
BenevolentAI
Investor Presentation
October 2022
poised for growth and success strengthened position enhances our leadership position in enabled drug discovery and enable us to independently pursue the clinical development of certain in house pipeline assets in core therapeutic areas out license multiple assets over the next years to strengthen our balance sheet and drive long term value creation increase the size of our pipeline with a healthy balance of new in class and best in class assets with stage drug candidates every year sign new collaboration agreements with companies to to leverage our disease agnostic capabilities into therapeutic indications outside our focus areas to generate incremental revenue maintain our leading position in target through increased investment in our technology capabilities build out our technology metrics to exemplify the differentiation of our approach | BenevolentAI
Bausch Health Companies
Investor Conference
March 2021
key salix pipeline overview overview | Bausch Health Companies
Renovacor
SPAC
October 2022
diversified pipeline of programs and therapeutic opportunities | Renovacor
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights